Status:
RECRUITING
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Lead Sponsor:
Assiut University
Conditions:
MIBC
mpMRI
Eligibility:
All Genders
18+ years
Brief Summary
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy ...
Detailed Description
Bladder cancer is a major global health concern, ranking as the sixth most common malignancy in males and the 17th most common in females, with an estimated annual incidence of approximately 550,000 n...
Eligibility Criteria
Inclusion
- Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.
- Planned to receive cisplatin-based NAC followed by radical cystectomy.
- Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).
Exclusion
- Patients who have received pelvic radiotherapy.
- Severe renal impairment
- Previous open or laparoscopic pelvic surgery.
- Presence of distant metastases at diagnosis.
- Patients with contraindications to MRI.
- Ineligibility to cisplatin
Key Trial Info
Start Date :
August 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT07202845
Start Date
August 29 2025
End Date
June 1 2026
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amr E. Darwish
Asyut, Egypt